Tempus Ai, INC 8-K filings

Tempus AI announced robust second quarter 2026 financial results, driven by significant year-over-year revenue growth in both Diagnostics and Data Licensing, leading to an increase in full-year revenue guidance.

Tempus AI, Inc. announced a definitive agreement to merge with Personalis, Inc. in a transaction structured as a two-step merger, with consideration to be paid in Tempus Class A common stock and potentially cash.

Tempus AI announced its definitive agreement to acquire Personalis, Inc. for $1.5 billion, aiming to integrate Personalis's MRD technology into its AI-enabled precision oncology platform.

Tempus AI announced first quarter 2026 financial results, showcasing significant year-over-year revenue growth and increased financial guidance for the full year.

Tempus AI, Inc. reported robust financial results for Q4 and full year 2025, driven by significant growth in diagnostics and data, alongside positive 2026 revenue and Adjusted EBITDA guidance.

Tempus AI announced preliminary unaudited financial results for Q4 and full year 2025, reporting significant revenue growth and record total contract value.

Tempus AI, Inc. reported strong third-quarter 2025 financial results, with revenue growing 84.7% year-over-year and achieving positive adjusted EBITDA.

Tempus AI, Inc. filed a prospectus supplement covering the resale of up to 1,268,033 shares of its Class A common stock by selling stockholders.

Tempus AI reported robust second-quarter 2025 financial results, with revenue surging 89.6% year-over-year and significantly improving its full-year 2025 financial guidance.

Tempus AI, Inc. has successfully completed a private offering of $750 million in 0.75% Convertible Senior Notes due 2030, using a significant portion of the proceeds to repay senior secured term loans and enhance financial flexibility.

Tempus AI held its 2025 Annual Meeting of Stockholders, where key proposals including the election of directors, ratification of the accounting firm, and approval of reincorporation were voted on.

Tempus AI announces a significant revenue increase and strategic collaborations, raising full-year revenue guidance to $1.25 billion.

Tempus AI collaborates with AstraZeneca and Pathos AI to develop a foundational large multimodal model in oncology, involving data licensing and financial transactions.

Tempus AI announces impressive financial results for Q4 and full year 2024, highlighted by accelerated revenue and gross profit growth, and anticipates positive Adjusted EBITDA in 2025 following the acquisition of Ambry Genetics.

Tempus AI finalizes a $300 million credit amendment to fund its acquisition of Ambry Genetics, enhancing its position in the genetic testing market.

Tempus AI reported preliminary unaudited results for the fourth quarter and full year 2024, showing significant revenue growth and exceeding expectations for both revenue and adjusted EBITDA.

Tempus AI has agreed to acquire Ambry Genetics from REALM IDx, Inc. for $375 million in cash and 4,843,136 shares of Tempus AI Class A common stock.

Tempus AI reported a 33% year-over-year revenue increase in Q3 2024 and announced the acquisition of Ambry Genetics to expand its genetic testing capabilities.

Tempus AI's Compensation Committee has deferred the settlement of approximately 4.47 million restricted stock units held by CEO Eric Lefkofsky until early 2025.

Tempus AI has made a significant investment in Personalis, acquiring shares and exercising warrants for a total of $36.18 million.

Tempus AI announced a 25% year-over-year revenue increase to $166 million in the second quarter of 2024, driven by strong growth in data licensing and strategic market expansions.

Tempus AI, Inc. has filed amended and restated certificate of incorporation and bylaws in connection with the closing of its initial public offering on June 17, 2024.